CD8A and neoplasm: This targeted nanovaccine effectively promotes DC maturation and antigen-specific CD8+ T cell activation in vitro and in vivo, demonstrating significant antitumor effects and improved survival in tumor-bearing mice with minimal systemic toxicity 81.